Compound makes imipenem 16 times more effective against antibiotic-resistant K. pneumoniae

NewsGuard 100/100 Score

North Carolina State University chemists have created a compound that makes existing antibiotics 16 times more effective against recently discovered antibiotic-resistant "superbugs."

These so-called superbugs are actually bacterial strains that produce an enzyme known as New Delhi metallo-β-lactamase (NDM-1). Bacteria that produce this enzyme are practically impervious to antibiotics because NDM-1renders certain antibiotics unable to bind with their bacterial targets. Since NDM-1 is found in Gram-negative bacteria like K. pneumoniae, which causes pneumonia, urinary tract, and other common hospital-acquired infections, it is of particular concern.

"To begin with, there are fewer antibiotic options for treating infections caused by Gram-negative bacteria than for those caused by Gram-positive bacteria," says Dr. Roberta Worthington, NC State research assistant professor of chemistry. "Gram-negative bacteria with the NDM-1enzyme effectively neutralize the few weapons we have in our arsenal, making them especially difficult, if not impossible, to treat with existing antibiotic therapy."

Previously, NC State chemist Dr. Christian Melander had found that a compound derived from a class of molecules known as 2-aminoimidazoles "recharged" existing antibiotics, making them effective against Gram-positive antibiotic-resistant bacteria like the Staphylococcus strain MRSA. So Melander, Worthington and graduate students Cynthia Bunders and Catherine Reed set to work on a variety of the compound that might prove similarly effective against their Gram-negative brethren.

In a paper published in ACS Medicinal Chemistry Letters, Worthington and Melander describe a compound that, when used in conjunction with the antibiotic imipenem, increased the antibiotic's effectiveness against the antibiotic-resistant K. pneumoniae 16-fold. The researchers believe that these early results are very promising for future treatments.

"We've demonstrated that we have the ability to take out the scariest superbug out there," Melander says. "Hopefully further research will allow us to make the compound even more effective, and make these infections little more than a nuisance."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study: Antibiotic use in moderate COVID-19 linked to clinical deterioration